3H Medi Solution
3H Medi Solution is a Tokyo-based, M3 Group subsidiary operating Japan's largest clinical trial volunteer platform (1.11M+ members) and providing integrated PRO, CRO, DCT, ePRO, and patient survey services to pharmaceutical, biotech, and healthcare clients across Japan and Asia.
- Company typePrivate
- Founded2009
- HeadquartersToshima, Japan
- Headcount251–500
- GTM typeB2B
- OfferingServices
What 3H Medi Solution does
3H Medi Solution (3Hメディソリューション株式会社) is a Tokyo-headquartered, privately held healthcare services company that operates Japan's largest direct-to-patient clinical trial volunteer platform and provides integrated clinical research services to pharmaceutical, biotech, and healthcare clients. Founded in 2005 as Limited Company Clinical Trial and rebranded under the M3 Group umbrella in 2022, 3H runs the Seikatsu Kojo WEB platform with 1.11M+ registered members, the Oncolo cancer portal, and the RareS rare disease portal — collectively reaching 11M+ monthly page views. The company also maintains proprietary technology including the P-Guardian ePRO system, the Uchiken DCT/eConsent platform, the cPhone standardized device rental service (10,000+ units deployed), and a clinical trials dashboard built on ClinicalTrials.gov data.
The company's core business spans patient recruitment (PRO), full-service CRO operations, decentralized clinical trial (DCT) implementation, ePRO deployment, patient survey and patient preference research, and marketing/promotion services through its owned media platforms. It maintains 225+ DCT-enabled clinical sites and 280+ GCP-qualified home nurses covering all of Japan, plus an Asia patient recruitment network spanning Korea, Taiwan, China, and India. Revenue is generated primarily through project-based professional services fees (PRO/CRO/DCT), supplemented by subscription/recurring IT licensing, hardware rental (cPhone), and unit-priced advertising on Seikatsu Kojo WEB.
Go-to-market is sales-led targeting enterprise pharmaceutical sponsors (90%+ of global Top 20 pharma and 100% of Japan Top 20 pharma have used the PRO service) complemented by event-driven thought leadership (Pharma IT & Digital Health Expo, SCOPE 2026) and ecosystem distribution via M3 Group's m3.com platform of 700K+ physicians. The company merged with subsidiary 3H Clinical Trial Inc. in May 2024 and is led by representative director Takizawa Hirotaka following a May 2023 leadership transition.
3H Medi Solution firmographics
Firmographics- Name
- 3H Medi Solution
- Legal name
- 3H Medi Solution Inc.
- Website
- https://3h-ms.co.jp
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- 3H Medi Solution is a Tokyo-based, M3 Group subsidiary operating Japan's largest clinical trial volunteer platform (1.11M+ members) and providing integrated PRO, CRO, DCT, ePRO, and patient survey services to pharmaceutical, biotech, and healthcare clients across Japan and Asia.
- Ownership category
- akta.pro rank
3H Medi Solution industry classification
Industry- Product category
- Clinical Research Services (Patient Recruitment, CRO, SMO, DCT)
- NAICS
- Home Health Care Services (62161), Scientific Research and Development Services (5417)
- SIC
- Services-Home Health Care Services (8082), Services-Health Services (8000)
- akta.pro primary industry
- Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH)
- akta.pro secondary industries
- Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Post-Acute & Hospital-at-Home Remote Care Platforms (HLACAFAB)
Keywords
Where 3H Medi Solution is headquartered
LocationHeadquarters
- HQ city
- Toshima
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
3H Medi Solution business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Patient Recruitment / PRO Services: Fees for patient recruitment (subject/monitor recruitment) services for clinical trials. Includes advertising, database querying, screening, and referral of qualified subjects to clinical trial sites. Part of SMO and CRO service bundles.
- CRO (Clinical Research Organization) Services: Full-service clinical research support including protocol design, IRB submissions, study management, data collection, statistical analysis, and medical writing. Conducted via subsidiary 3H Clinical Trial and partnerships.
- DCT (Decentralized Clinical Trial) Services: Bundle of services including eConsent, ePRO, home nursing, device rental/provisioning for decentralized trials. Revenue from study-specific project fees.
- Patient Survey / Market Research: Patient-centered research services including qualitative interviews, quantitative surveys, MROC (online community), discrete choice experiments, and patient journey mapping. Also includes PPS (Patient Preference Studies) for regulatory submissions.
- Promotion / Advertising Services: Marketing and promotion services leveraging the Seikatsu Kojo WEB platform. Includes email newsletter advertising, LINE messaging campaigns, and website banner placements with audience segmentation.
- IT / Healthcare Technology Solutions: ePRO system (P-Guardian), clinical data platforms, app development, and DCT technology systems. May include subscription or per-study licensing components.
- Device Rental (cPhone): Rental of standardized smartphones and IoT devices for clinical trials. Fees based on contract duration and device specifications.
- Biological Sample Recruitment Services: Recruitment of patients willing to provide biological samples (blood, urine, tissue) for research. Matches patients to researchers under ethical oversight frameworks (PCRD2).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Monthly | Email newsletter advertising with four volume tiers from 4,000 to 100,000+ sends |
| Unit Pricing | Pay-as-you-go | LINE messaging at 20 JPY per message with demographic segmentation |
Go-to-market motion2 records
Distribution channels9 records
Marketing channels10 records
3H Medi Solution product offering
Product offeringCore offering
3H Medi Solution provides end-to-end clinical trial support services for pharmaceutical, biotech, and medical device sponsors, including patient recruitment (PRO) sourced from Japan's largest direct-to-patient volunteer database (~1.1M registered members), CRO and SMO clinical research operations, decentralized clinical trial (DCT) execution via its Uchiken platform and 280+ GCP-qualified home nurses, electronic patient-reported outcome collection through its 3H P-Guardian system, clinical-trial device rental through cPhone, and patient survey / patient preference (PPS) research. The company also operates consumer-facing patient media platforms (Seikatsu Kojo WEB, Oncolo, RareS) that feed its recruitment funnel and support advertising-based promotion services.
Differentiator
Problem solved
Functional benefit
Brands
- Uchiken (ウチケン): Visit nursing station specialized in clinical trials; provides home-based clinical trial support services for DCT implementation
- 3H P-Guardian (スリーエイチピーガーディアン)
- cPhone
- 生活向上WEB「マイカルテ」(Seikatsu Kojo WEB My Karute)
- Clinical Trials Dashboard
- 患者インサイトパック (Patient Insight Pack)
- PCRD² (Patient Centricity in Rare Disease R&D Program)
Products and services
- Patient Recruitment (PRO) Services Advertising, database querying, screening, and referral of qualified subjects to clinical trial sites; bundled with SMO and CRO services for pharma and biotech sponsors.
- CRO (Clinical Research Organization) Services Full-service clinical research support including protocol design, IRB submissions, study management, data collection, statistical analysis, and medical writing, delivered via subsidiary 3H Clinical Trial and partnerships.
- SMO (Site Management Organization) Services Site management services supporting hospitals and clinics conducting clinical trials, including coordinator staffing, SOP development, and trial site operations.
- DCT (Decentralized Clinical Trial) Support Services Bundle of services including eConsent (Uchiken), ePRO, home nursing (Uchiken visiting nurses), and cPhone device rental for decentralized clinical trials, with study-specific project fees.
- 3H P-Guardian ePRO System Electronic patient-reported outcome (ePRO) system for clinical research and real-world practice, enabling real-time data collection via smartphone/tablet, with questionnaire scheduling, alerts, PDF/CSV export, caregiver sharing, and regulatory compliance.
- Uchiken DCT / eConsent Platform Remote electronic consent (eConsent) platform combining Zoom Meeting video conferencing and DocuSign eSignature, supporting online informed consent for clinical trials without in-person hospital visits, with version management, multi-party meetings, audit trails, and PDF reports.
- cPhone Device Rental Service Standardized smartphone rental service for clinical trial participants, providing a unified device environment with restricted apps, DTx trial device assignment, remote lock/wipe, and 24/7 helpdesk, with over 10,000 units deployed.
- Patient Survey and Patient Preference Study (PPS) Services Patient-centered research services including qualitative interviews, quantitative surveys, MROC (online community), discrete choice experiments, and patient journey mapping; PPS for regulatory submissions (ICH E22 compliance).
- Asia Patient Recruitment Network (APRO) Pan-Asian patient recruitment services enabling coordinated cross-border clinical trial patient recruitment across Asian countries via partners in Korea, Taiwan, China, and India.
- PCRD2 Patient-Centricity in Rare Disease R&D Program Framework for matching rare disease patients who wish to participate in research with investigators needing specimens and health information, including ethical committee review and patient feedback of research results.
- Seikatsu Kojo WEB Patient Platform and Promotion Services Japan's largest direct-to-patient clinical trial volunteer platform with 1.1M+ registered members and 220+ disease category PHR data, used for clinical trial recruitment funnels and promotional/advertising services.
- Oncolo Cancer Information Portal Oncology-focused information portal with 200K+ monthly unique visitors, providing cancer clinical trial information, expert seminars, and patient support content; co-hosts 40+ online seminars per year with cancer research organizations.
- RareS Rare Disease Portal Rare disease information and community platform covering 330 designated intractable diseases and 47 rare cancers, connecting patient advocacy groups with rare disease patients.
- Biological Sample Recruitment Services Recruitment of patients willing to provide biological samples (blood, urine, tissue) for research, matching patients to researchers under ethical oversight frameworks including PCRD2.
- DCT Implementation PoC Service Proof-of-concept service for DCT adoption including study planning, device selection, app development, patient recruitment, IRB support, and RAW data delivery; covers 15+ completed PoC cases.
- Help Desk and Administrative Support Services Call center and administrative support for clinical trials, including inbound/outbound patient calls, study coordination, and 24/7 helpdesk support, anchored by the Miyazaki Contact Center.
Quantifiable outcome
- 10,000+ patient randomizations per year
- +5 more outcomes
Companies that use 3H Medi Solution
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles4 records
3H Medi Solution technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability6 records
Feature12 records
3H Medi Solution partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered minor, core and flagship.
- Merck BioPharma (メルクバイオファーマ)minorCollaboration to launch 'Oncolo for Seniors' (オンコロforシニア), a simplified cancer information website for elderly patients, operated by Oncolo with Merck BioPharma.
- GeneQuest (株式会社ジーンクエスト)coreJoint research collaboration to build patient registries combining genetic information with clinical data. Successfully constructed IBD (inflammatory bowel disease) patient registry of 100 patients. Also built genetic + clinical database for pharmacogenomic analysis and precision patient recruitment.
- AstraZenecaminorOncolo cancer portal collaboration on gastric cancer awareness campaigns with AstraZeneca.
- QLife (株式会社QLife)coreJoint patient recruitment services combining 3H's clinical trial volunteer database with QLife's patient media platforms and healthcare provider network. Combined PRO operations serve the M3 Group ecosystem.
- THREAD Researchcore3H became a certified implementation partner for THREAD's DCT platform in Japan. 3H provides patient recruitment, home nursing, and DCT consulting services integrated with THREAD's technology platform for sponsors adopting DCT in Japan.
- Four H (合同会社Four H)minorJoint venture company established with HYPER CUBE for specialized clinical research services.
- M3 Group (エムスリーグループ)flagship3H became part of the M3 Group in February 2022, gaining access to M3's ecosystem including 700K+ physicians on m3.com, integrated CRO/SMO services (MediScience Planning, Noes), home nursing (Sofia Med), and patient recruitment synergies across the group.
- Science 37coreStrategic partnership to enable DCT (decentralized clinical trials) and promote patient enrollment in Japan. Science 37 provided its DCT technology platform while 3H contributed patient recruitment and home nursing capabilities.
- Patient Centricity Promotion Center (Patient Centricity推進センター)coreParticipation in the Patient Centricity Promotion Center co-founded by MediScience Planning and QLife (2021). Aims to accelerate patient-centric drug development in Japan through PPI (Patient and Public Involvement).
- Eisai Healthcare (エイツーヘルスケア)minorBusiness partnership aimed at promoting patient engagement in drug development. Combined 3H's patient recruitment and survey capabilities with Eisai's pharmaceutical development expertise.
- Tokyo University / 3H Holdings / Neo Pharma JapancoreLaunched Patient Centricity in Rare Disease R&D Program (PCRD2) to connect rare disease patients willing to participate in research with investigators needing specimens and health information.
- Tokyo University Graduate School of Pharmaceutical Sciences (東京大学 大学院薬学系研究科)coreIT Healthcare Social Collaboration Research joint research program (2018-2021). Co-developed PCRD2 (Patient Centric Rare Disease R&D Program) with Tokyo University for matching rare disease patients with researchers. Includes research themes on DCT paradigm shift and patient-centric drug development.
- Intellim (インテリム)minorPartnership with Intellim for the Oncolo cancer portal, combining oncology clinical trial information and support services.
- EPS (イーピーエス)minorStrategic cooperation in patient recruitment with EPS, one of Japan's largest CROs.
- Asia Patient Recruitment Network (APRO)coreFirst Asia-based patient recruitment network established by 3H, enabling coordinated cross-border clinical trial patient recruitment across Asian countries.
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
3H Medi Solution competitors and assessment
Company assessmentMarket position
Strengths1 record
Competitive moat6 records
Key risks2 records
Key highlights7 records
Customer concentration
3H Medi Solution social profiles
Digital presence3H Medi Solution financial estimates
Financial estimateRevenue estimate
Valuation estimate
3H Medi Solution leadership team
Management profileNumber of profiles
Profiles7 records
3H Medi Solution subsidiaries and ownership
Company hierarchySubsidiaries3 records
3H Medi Solution funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
3H Medi Solution M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 3H Medi Solution
What does 3H Medi Solution do?
3H Medi Solution provides end-to-end clinical trial support services for pharmaceutical, biotech, and medical device sponsors, including patient recruitment (PRO) sourced from Japan's largest direct-to-patient volunteer database (~1.1M registered members), CRO and SMO clinical research operations, decentralized clinical trial (DCT) execution via its Uchiken platform and 280+ GCP-qualified home nurses, electronic patient-reported outcome collection through its 3H P-Guardian system, clinical-trial device rental through cPhone, and patient survey / patient preference (PPS) research. The company also operates consumer-facing patient media platforms (Seikatsu Kojo WEB, Oncolo, RareS) that feed its recruitment funnel and support advertising-based promotion services.
Is 3H Medi Solution a public or private company?
3H Medi Solution is a private company. It is classified as corporate owned and is currently operating.
When was 3H Medi Solution founded?
3H Medi Solution was founded in 2009. It employs 251 to 500 people.
Where is 3H Medi Solution based?
3H Medi Solution is headquartered in Toshima, Japan, in the Asia region.
How does 3H Medi Solution make money?
Eight revenue lines are on record. Patient Recruitment / PRO Services are the primary driver. The others are CRO (Clinical Research Organization) Services, DCT (Decentralized Clinical Trial) Services, patient Survey / Market Research, promotion / Advertising Services, IT / Healthcare Technology Solutions, device Rental (cPhone) and biological Sample Recruitment Services.
Does 3H Medi Solution have an API?
No public API is recorded for 3H Medi Solution.
What industry is 3H Medi Solution in?
3H Medi Solution's product category is Clinical Research Services (Patient Recruitment, CRO, SMO, DCT). Its primary akta.pro industry code is HLAGACAH, Decentralized & Hybrid Trial Site Services (Home Health/Nursing), with a secondary code of HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote). Its NAICS code is 62161 and its SIC code is 8082.